Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is viewed favorably because its core radiopharmaceutical franchise continues to show resilience, with 1Q26 revenue of $377 million and adjusted EPS of $1.46 both ahead of expectations, while PYLARIFY delivered a third consecutive quarter of stable or improving revenue and gross margin held at 67.0%. The outlook is further supported by multiple 2026 catalysts, including FDA approval for PYLARIFY TruVu, tentative approval for PNT2003, and the upcoming MK6240 decision, alongside the company’s ability to grow across segments with DEFINITY, Neuraceq, and strategic partnerships contributing meaningfully. Even with the CRL for LNTH-2501, the FDA cited no concerns about safety or efficacy and only third-party manufacturing issues, reinforcing a path to eventual approval while the company’s margin expansion, de-risked estimates, and expected 2027 re-acceleration strengthen the fundamental thesis.

Bears say

Lantheus Holdings is vulnerable because more than 80% of total sales in 2022 came from PYLARIFY and DEFINITY, leaving the business highly concentrated and exposed to any disruption in either platform. Competition for both products, along with just-in-time manufacturing constraints tied to limited half-life radioisotopes and reliance on a nationwide PMF and cyclotron network, creates meaningful execution and supply-chain risk that could quickly impair revenue and service reliability. Reimbursement and regulatory pressure from third-party payors and Medicare adds another layer of downside, while pricing/share headwinds, potential delays for “PYL 2.0,” integration of LMI/Evergreen, and the CEO transition increase the risk of operational underperformance.

Lantheus Holdings (LNTH) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 5 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.